Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Therapy: Clinical

Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression

Emanuela Romano, Sylvain Pradervand, Alexandra Paillusson, Johann Weber, Keith Harshman, Katja Muehlethaler, Daniel Speiser, Solange Peters, Donata Rimoldi and Olivier Michielin
Emanuela Romano
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Pradervand
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Paillusson
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johann Weber
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Harshman
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Muehlethaler
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Speiser
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solange Peters
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donata Rimoldi
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Michielin
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-13-0661 Published October 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2013 to January 2021

AbstractFull-text HTMLPDF
Total850827292719

Cited By

Article Information

Volume 19, Issue 20, pp. 5749-5757

DOI 
https://doi.org/10.1158/1078-0432.CCR-13-0661
PubMed 
23948972

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received March 8, 2013
  • Revision received June 13, 2013
  • Accepted July 30, 2013
  • Published first August 15, 2013.

Article Versions

  • Previous version (August 15, 2013 - 07:47).
  • Previous version (September 12, 2013 - 09:23).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2013 American Association for Cancer Research.

Author Information

  1. Emanuela Romano1,
  2. Sylvain Pradervand2,3,
  3. Alexandra Paillusson2,
  4. Johann Weber2,
  5. Keith Harshman2,
  6. Katja Muehlethaler4,
  7. Daniel Speiser4,
  8. Solange Peters1,
  9. Donata Rimoldi4, and
  10. Olivier Michielin1,4
  1. Authors' Affiliations: 1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland
  1. Corresponding Authors:
    Olivier Michielin, Department of Oncology, Rue du Bugnon 21, Lausanne 1011, Switzerland. Phone: 41-79-556-6027; Fax: 41-21-314-0200; E-mail: olivier.michielin{at}chuv.ch; Sylvain Pradervand, Genopode, 1015 Lausanne, Switzerland. Phone:41-21-692-3908. Email: sylvain.pradervand{at}unil.ch; and Donata Rimoldi, Ludwig Center for Cancer Research of the University of Lausanne, chemin des Boveresses 155, 1066 Epalinges, Switzerland; E-mail:donata.rimoldi{at}unil.ch
  1. E. Romano and S. Pradervand contributed equally to this work.

View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 19 (20)
October 2013
Volume 19, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano, Sylvain Pradervand, Alexandra Paillusson, Johann Weber, Keith Harshman, Katja Muehlethaler, Daniel Speiser, Solange Peters, Donata Rimoldi and Olivier Michielin
Clin Cancer Res October 15 2013 (19) (20) 5749-5757; DOI: 10.1158/1078-0432.CCR-13-0661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano, Sylvain Pradervand, Alexandra Paillusson, Johann Weber, Keith Harshman, Katja Muehlethaler, Daniel Speiser, Solange Peters, Donata Rimoldi and Olivier Michielin
Clin Cancer Res October 15 2013 (19) (20) 5749-5757; DOI: 10.1158/1078-0432.CCR-13-0661
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Biomarker Analysis from the BERIL-1 Study
  • Radiation and TGFβ Blockade in Metastatic Breast Cancer
  • Analyses of Associations between PFS and OS in IO Trials
Show more Cancer Therapy: Clinical
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement